Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

24-hour diastolic ambulatory blood pressure and mean seated office systolic and diastolic blood pressure as well as a number of other endpoints.

Investor event at ASH

Pharmacopeia will host a meeting for investors today, Friday, May 16th at 7:00am CDT (8:00am EDT) to review the Phase 2a study results from its PS433540 program, including a presentation by Joel Neutel, M.D., the study's lead investigator. A live webcast and 90-day archive of the presentation can be accessed on the Investors section of the company's website at http://www.pharmacopeia.com.

About PS433540

PS433540 is the first and only blood pressure product candidate in a new class of antihypertensives known as Dual Acting Receptor Antagonists (DARAs). PS433540 is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540 possesses two clinically validated mechanisms of action in a single molecule. There is preclinical and initial clinical data suggesting that compared to either mechanism alone, simultaneously blocking angiotensin II and endothelin 1 at their respective receptors, AT1 and ETA, may provide an improved treatment option for several cardiovascular diseases. Because PS433540 is highly selective for the AT1 and ETA receptors it is able to block the blood pressure-raising actions of angiotensin and endothelin when they bind to these receptors.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including eight clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The compa
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Oct. 7 All American gymnast, wife and mom-to-be Shannon ... expecting her first baby in late October and has been ... best possible start on life and learning. Now she,s ... moms around the world. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091007/DE88885 ...
... suspect , WEDNESDAY, Oct. 7 (HealthDay News) -- Younger people ... an anterior cruciate ligament repaired, a new study has ... commonly called an ACL. , ACL damage is one of ... data from more than 70,000 people in New York who ...
... those with, without device , WEDNESDAY, Oct. 7 (HealthDay News) ... heart attack does not improve survival, a major European study ... those given the devices, which shock the heart into beating ... as for those who did not get defibrillators in the ...
... Global TV Concepts, manufacturer and creator of the ... World Record title for the ,World,s Largest Cupcake., Weighing ... feet tall and six feet wide, the massive cupcake was ... from slices of the confectionary masterpiece supported breast cancer charities. ...
... Company,s (NYSE: CRDA ; CRDB) European third party ... name of Broadspire, a Crawford company, continuing the leading ... CRDA ; CRDB), the world,s largest independent provider ... the Broadspire brand at the Federation of European Risk ...
... US Farms, Inc. (Pink Sheets: USFM) today announced that it ... ( www.edisastersystems.com ) based out of City of ... , Yan Skwara, CEO for US Farms, Inc. ... and soothing burns and having our Aloe365(TM) Skin Gel registered ...
Cached Medicine News:Health News:Country's Most Decorated Gymnast New Spokesmom for BabyPlus 2Health News:2nd Knee Surgery Common Among Young Patients 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 3Health News:Big Top Cupcake(TM) Brand Awarded With Guinness World Record For World's Largest Cupcake 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 2Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 3Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 4
Skin Tone External Eyelid Weights...
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Zone Quick is a simple and accurate system that measures tear volume in just 15 seconds per eye. Each box has an easy to read diagnostic indicator rule....
... Stent has been introduced by FCI Ophthalmics, Inc. ... Lacrimal Stent addressed the limitations previously encountered with ... DCR. Brought in to position through the nose, ... is no need to pass the very large ...
Medicine Products: